The US FDA restricts the use of the GlaxoSmithKline-Vir COVID-19 drug
The US FDA restricts the use of the GlaxoSmithKline-Vir COVID-19 drug

The US FDA restricts the use of the GlaxoSmithKline-Vir COVID-19 drug

Signage seen outside Food and Drug Administration (FDA) headquarters in White Oak, Maryland, USA, August 29, 2020. REUTERS / Andrew Kelly

Sign up now for FREE unlimited access to Reuters.com

February 23 (Reuters) – The US Food and Drug Administration said on Wednesday GlaxoSmithKline (GSK.L) and Vir Biotech’s (VIR.O) COVID-19 antibody therapy should not be used in sites with circulation of variants that are not susceptible to the drug.

Vir has said that the drug, sotrovimab, retains its neutralizing activity against the new BA.2 form of the Omicron coronavirus variant.

However, other recent research suggests that the variant showed resistance to almost all of the monoclonal antibodies they tested, including sotrovimab. Read more

The GSK-Vir drug is one of the few COVID-19 treatments that have been shown to have worked against the original Omicron variant, which spurred demand.

The United States had briefly halted the distribution of other Regeneron antibody drugs (REGN.O) and Eli Lilly (LLY.N) over concerns that they are not working against Omicron.

Sign up now for FREE unlimited access to Reuters.com

Reporting of Manas Mishra in Bengaluru; Editing by Maju Samuel

Our standards: Thomson Reuters trust principles.

Leave a Reply

Your email address will not be published.